Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Europe's drug regulator recommends Sogroya for three new pediatric indications — idiopathic short stature, small-for-gestational-age growth failure, and Noonan syndrome. If the European Commission signs off, Sogroya (somapacitan) would become the first and only growth hormone therapy authorized for idiopathic short stature in the EU. The once-weekly injection could replace daily shots for thousands of children across Europe.
Europe's top drug advisory committee has recommended expanding the use of Sogroya (somapacitan, Novo Nordisk) to cover three new pediatric growth conditions: idiopathic short stature (ISS), growth failure in children born small for gestational age (SGA) who haven't caught up, and Noonan syndrome. The recommendation follows a re-examination of an earlier May 2026 opinion and now heads to the European Commission for a final decision, expected within roughly 67 days.
The biggest milestone here is ISS — a condition affecting up to 3% of children worldwide where kids are significantly shorter than peers with no identifiable cause. Because diagnosis requires ruling out other conditions first, children are often identified late, shrinking the treatment window. If approved, Sogroya would be the first and only EU-authorized growth hormone therapy for ISS, filling a gap where GH has historically been used off-label or not at all across many EU countries. Sogroya works by binding to albumin in the bloodstream, slowing its clearance and enabling once-weekly dosing instead of daily injections — cutting annual injections from 365 to 52.
By the Numbers:
Why it matters: This expansion could standardize growth hormone access for children with ISS across the EU, where treatment has been inconsistent, while also reducing the injection burden for families managing Noonan syndrome and SGA-related growth failure.
